Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9I3WE
|
|||
| Drug Name |
SYN120
|
|||
| Synonyms |
Landipirdine; 1000308-25-7; UNII-J0NX985GDI; J0NX985GDI; CHEMBL1082508; RO5025181; RO5025181-000; N-(((1R)-6-(3-fluorobenzenesulfonyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)urea; Landipirdine [USAN]; Landipirdine (USAN/INN); SCHEMBL315956; SYN-120; BDBM50416003; SB18761; D11157; Q27896229; R05025181; R0-5025181; R0-5025181-000; R05025181-000; (R)-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea; [(1R)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea; Urea, N-(((1R)-6-((3-fluorophenyl)sulfonyl)-1,2,3,4-tetrahydro-1-naphthalenyl)methyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [1] | |
| Company |
Acorda Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H19FN2O3S
|
|||
| Canonical SMILES |
C1CC(C2=C(C1)C=C(C=C2)S(=O)(=O)C3=CC=CC(=C3)F)CNC(=O)N
|
|||
| InChI |
1S/C18H19FN2O3S/c19-14-5-2-6-15(10-14)25(23,24)16-7-8-17-12(9-16)3-1-4-13(17)11-21-18(20)22/h2,5-10,13H,1,3-4,11H2,(H3,20,21,22)/t13-/m0/s1
|
|||
| InChIKey |
MTTHRRVVGMPYQG-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 1000308-25-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Antagonist | [2] |
| 5-HT 6 receptor (HTR6) | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Gap junction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT2 type receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | |||
| Reactome | Serotonin receptors | |||
| G alpha (s) signalling events | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02258152) SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (SYNAPSE). U.S. National Institutes of Health. | |||
| REF 2 | Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.